Abstract:Background: The Women’s Interagency HIV Study was established in 1993 to study the natural history of HIV disease among women in the United States. It currently has enrolled 2,895 women testing positive for HIV infection and 972 women without HIV infection recruited from 6 national metropolitan locations. The clinical database information collected for each HIV-positive individual included CD4 cell counts, viral load, and antiviral treatment to evaluate HIV prognosis and related conditions in women. Objective: To provide a baseline for fluconazole treatment prospects in women who test positive for HIV infection. As part of the ongoing Women’s Interagency HIV Study project, we investigated the fluconazole susceptibility of Candida spp. isolated from women with HIV in comparison to volunteer women without HIV. The implication of antifungal treatment on fluconazole susceptibility was evaluated by reviewing antifungal medication use for the past 2 years in each participant. In addition, genotyping of Candida spp. at oral and vaginal sites was monitored for 4 months in 9 patients. Methods: In a cohort of 59 women with HIV and 24 women without HIV, colonization by Candida albicans and non-albicans species of the oral and vaginal sites was first determined. Fluconazole susceptibility was surveyed in vitro according to Clinical and Laboratory Standards Institute protocol. Antifungal drug treatment history was investigated for each patient to correspond with fluconazole susceptibility. Finally, series of isolates from several patients were followed for resistance and susceptibility. Their lineage was verified by genotyping multilocus sequence typing (MLST). Results: A total of 280 Candida strains were recovered from oral and vaginal swabs of women with and without HIV infection. We found that patients with HIV were colonized with Candida spp. more frequently than women without HIV. The percent of isolates that were susceptibility dose dependent or resistant to fluconazole was higher in Candida glabrata compared with C. albicans isolates, but higher for C. albicans than other published data. Resistance was noted to be more common in vaginal sites. Fluconazole resistance in either species was not associated with relative CD4 cell counts or viral load. However an association with systemic application of fluconazole and resistance was noted. Conclusions: Systemic antifungal therapy, including a vaginal topical regimen in women with HIV infection correlated with reduced fluconazole susceptibility of oral and vaginal isolates. Genotype profiling has disclosed that a majority of isolates from the same individual are clustered together, suggesting the likelihood of an original strain with some microevolution. We observed a change from a susceptibility dose dependent to a resistant phenotype of isolates in 2 women with HIV infection, even though no treatments were received during the 4-month study and the prior 2 years.

Species distribution and antifungal susceptibility of Candida sp. isolates from AIDS patients with oropharyngeal candidiasis

Distribution and Antifungal Susceptibility of Candida Species Causing Candidemia in China: an Update from the CHIF-NET Study

Clinical Research of Fungal Infection in 296 AIDS Patients

Identification of fungal strains isolated from AIDS patients and analysis of their antifungal sensitivity

Susceptibility of non-Candida albicans isolates to common antifungal agents

Species identification and antifungal susceptibility of 128 strains of yeast fungi

Invasive Candidiasis in Intensive Care Units in China: in Vitro Antifungal Susceptibility in the China-SCAN Study

In Vitro Antidrug Susceptibility Testing of Candida Species Isolated from Aseptic Body Fluids

Oral candidiasis fl ora distribution and antifungal susceptibility test in vitro studies

SPECIES DISTRIBUTION OF CANDIDEMIA AND SUSCEPTIBILITY TO FLUCONAZOLE

Genotyping and Antifungal Susceptibility of Candida Albicans Isolates from AIDS Patients

Antifungal Susceptibilities of Cryptococcus Species Complex Isolates from AIDS and Non-Aids Patients in Southeast China

Fluconazole susceptibility of 3,056 clinical isolates of Candida species from 2005 to 2009 in a tertiary-care hospital

Drug-resistance of oral cultured candida spp.In HIV positive patients

Antifungal Susceptibility Testing of Commensal and Pathogenic Clinical Isolates of Oral Candida

Epidemiology of Oral Candidiasis in HIV-infected Patients: Colonization, Infection, Treatment, and Emergence of Fluconazole Resistance

Frequency and species distribution of Candida in oral cavity of human immunodeficiency virus-infected patients

Clinical Distribution and Drug Sensitivity of 486 Strains of Candida in 1,690 Specimens

Analysis of antifungal susceptibility in vitro and fungi distribution in clinics

In vitro susceptibilities of yeast species to fluconazole and voriconazole as determined by the 2010 National China Hospital Invasive Fungal Surveillance Net (CHIF-NET) study.

Fluconazole Resistance Patterns in Candida Species That Colonize Women with HIV Infection